Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Opening stock page...
Fetching company snapshot, pricing, and intelligence.
AI confidence 48% · prior close shown (market closed)
ImmunityBio, Inc. execution reads as mixed on proprietary earnings and initiative evidence.
Why it matters: ANKTIVA Commercial Launch.
Priority: QUILT-2.005 Trial..
3 signals not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 33d ago
Reported figures for ImmunityBio, Inc. — research only, not investment advice.
Updated
What happened recently for ImmunityBio, Inc. (IBRX) — events, not interpretation.
Research & analysis only — not investment advice.
Investment snapshot
Prior close
$7.57
Market cap
$8.02B
Profitable
No
Revenue $113.29M
Net income
$-351.40M
FY Dec 31, 2025
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for ImmunityBio, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Connected companies and research pages from the AlphaOS knowledge graph.
Follow ImmunityBio, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.